stockrowCareDx, Inc.
CDNA Healthcare Diagnostics & Research
CareDx, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $379.8 million, up 13.8% from fiscal 2024.
- Revenue
- +39.3%
- EPS
- +1,133.3%
- Free cash flow
- −68.6%
Quarter to September 2026, against a year earlier
Follow CDNA
Alert me
CareDx, Inc. (CDNA) Revenue growth
CareDx, Inc.'s revenue growth over the twelve months to 30 September 2026 was 38.9%, up 25.2 percentage points from fiscal 2025 (13.8%). Over the past ten years it has ranged from −12.9% (fiscal 2023) to 66.0% (fiscal 2019); the current reading is higher than 36% of that period. That is above the Diagnostics & Research industry median of 8.99% and above the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 13.8% | (5.28) |
| FY2024 | 19.1% | 31.96 |
| FY2023 | −12.9% | (21.46) |
| FY2022 | 8.57% | (45.65) |
| FY2021 | 54.2% | 2.97 |
| FY2020 | 51.3% | (14.70) |
| FY2019 | 66.0% | 7.50 |
| FY2018 | 58.5% | 39.52 |
| FY2017 | 18.9% | (25.44) |
| FY2016 | 44.4% | 41.30 |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 39.3% | (12.94) |
| Jun 2026 | 52.2% | 13.24 |
| Mar 2026 | 39.0% | 13.80 |
| Dec 2025 | 25.2% | 4.47 |
| 43 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| BLLN BillionToOne, Inc. compare | 76.5% |
| CDNA CareDx, Inc. | 38.9% |
| WGS GeneDx Holdings Corp. compare | 25.4% |
| RDNT RadNet, Inc. compare | 18.9% |
| ADPT Adaptive Biotechnologies Corporation compare | 17.9% |
| VCYT Veracyte, Inc. compare | 17.5% |
| GRAL GRAIL, Inc. compare | 17.5% |
| NEO NeoGenomics, Inc. compare | 11.1% |
| SHC Sotera Health Company compare | 6.90% |
| Diagnostics & Research industry median | 8.99% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on CDNA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement